Latest advances in clinical studies of circulating tumor cells in early and metastatic breast cancer
Copyright © 2023. Published by Elsevier Inc..
Circulating tumor cells (CTCs) have emerged as a promising biomarker in breast cancer, offering insights into disease progression and treatment response. While CTCs have demonstrated prognostic relevance in early breast cancer, more validation is required to establish optimal cut-off points. In metastatic breast cancer, the detection of CTCs using the Food and Drug Administration-approved CellSearch® system is a strong independent prognostic factor. However, mesenchymal CTCs and the Parsortix® PC1 system show promise as alternative detection methods. This chapter offers a comprehensive review of clinical studies on CTCs in breast cancer, emphasizing their prognostic and predictive value in different stages of the disease and provides insights into potential future directions in CTC research.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:381 |
|---|---|
| Enthalten in: |
International review of cell and molecular biology - 381(2023) vom: 22., Seite 1-21 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Munoz-Arcos, Laura S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Completed 25.09.2023 Date Revised 27.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/bs.ircmb.2023.07.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362359865 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362359865 | ||
| 003 | DE-627 | ||
| 005 | 20231226091057.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/bs.ircmb.2023.07.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362359865 | ||
| 035 | |a (NLM)37739480 | ||
| 035 | |a (PII)S1937-6448(23)00119-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Munoz-Arcos, Laura S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Latest advances in clinical studies of circulating tumor cells in early and metastatic breast cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.09.2023 | ||
| 500 | |a Date Revised 27.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Inc. | ||
| 520 | |a Circulating tumor cells (CTCs) have emerged as a promising biomarker in breast cancer, offering insights into disease progression and treatment response. While CTCs have demonstrated prognostic relevance in early breast cancer, more validation is required to establish optimal cut-off points. In metastatic breast cancer, the detection of CTCs using the Food and Drug Administration-approved CellSearch® system is a strong independent prognostic factor. However, mesenchymal CTCs and the Parsortix® PC1 system show promise as alternative detection methods. This chapter offers a comprehensive review of clinical studies on CTCs in breast cancer, emphasizing their prognostic and predictive value in different stages of the disease and provides insights into potential future directions in CTC research | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Clinical utility | |
| 650 | 4 | |a Human epidermal growth factor receptor 2 | |
| 650 | 4 | |a Liquid biopsy | |
| 650 | 4 | |a Predictive value | |
| 650 | 4 | |a Prognostic value | |
| 700 | 1 | |a Nicolò, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Serafini, Mara S |e verfasserin |4 aut | |
| 700 | 1 | |a Gerratana, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Reduzzi, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Cristofanilli, Massimo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International review of cell and molecular biology |d 2008 |g 381(2023) vom: 22., Seite 1-21 |w (DE-627)NLM180124633 |x 1937-6448 |7 nnns |
| 773 | 1 | 8 | |g volume:381 |g year:2023 |g day:22 |g pages:1-21 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/bs.ircmb.2023.07.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 381 |j 2023 |b 22 |h 1-21 | ||